Role of FDG-PET in surgical management of patients with colorectal liver metastases

ANZ Journal of Surgery

Volumn 74, Issue 8, 2004, Pages 646-652

  Teague, Benjamin D ^a   Morrison, Charles P ^a   Court, Fiona G ^a   Chin, Venessa T ^a   Costello, Samuel P ^a   Kirkwood, Ian D ^b   Maddern, Guy J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Colorectal cancer; Computerized tomography; Hepatectomy; Liver metastases; Positron emission spectroscopy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DATA BASE; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; LIVER METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY;

AGED; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 4444305226     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-1433.2004.02948.x     Document Type: Article

References (24)

1. Berry D, Maddern G. Other in-situ ablative techniques for unresectable liver tumours. Asian J. Surg. 2000; 23: 22-31.
2. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J. Clin. 1999; 49: 231-55.
3. Thomas R (ed). NHMRC Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer: Commonwealth Department of Human Services and Health, Australia. Canberra: Government Publishing Services 1999.
4. Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br. J. Surg. 1999; 86: 158-69.
5. Bengmark S. Palliative treatments of hepatic tumours. Br. J. Surg. 1989; 76: 771-3.
6. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J. Surg. 1995; 19: 59-71.
7. Teague BD, Wemyss-Holden SA, Fosh BG, Dennison AR, Maddern GJ. Electrolysis and other local ablative treatments for non-resectable colorectal liver metastases. ANZ J. Surg. 2002; 72: 137-41.
8. Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann. Surg. 2001; 233: 293-9.
9. John TG, Greig JD, Crosbie JL, Miles WF, Garden OJ. Superior staging of liver tumors with laparoscopy and laparoscopic ultrasound. Ann. Surg. 1994; 220: 711-19.
10. Rahusen FD, Cuesta MA, Borgstein PJ et al. Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography. Ann. Surg. 1999; 230: 31-7.
11. Yonekura Y, Benua RS, Brill AB et al. Increased accumulation of 2-deoxy-2-[18F]fluoro-d-glucose in liver metastases from colon carcinoma. J. Nucl. Med. 1982; 23: 1133-7.
12. Beets G, Penninckx F, Schiepers C et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br. J. Surg. 1994; 81: 1666-70.
13. Fong Y, Saldinger P, Akhurst T et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am. J. Surg. 1999; 178: 282-7.
14. Lai DTM, Fulham M, Stephen MS et al. The role of whole-body positron emission tomography with [(18) F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch. Surg. 1996; 131: 703-7.
15. Meta J, Seltzer M, Schiepers C et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J. Nucl. Med. 2001; 42: 586-90.
16. Zervos EE, Badgwell BD, Burak WE, Arnold MW, Martin EW. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiological workup. Surgery 2001; 130: 636-44.
17. Delbeke D, Vitola JV, Sandler MP et al. Staging recurrent metastatic colorectal carcinoma with PET. J. Nucl. Med. 1997; 38: 1196-201.
18. Ruers TJM, Langenhoff BS, Neeleman N et al. Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal metastases: a prospective study. J. Clin. Oncol. 2002; 20: 388-95.
19. Huebner RH, Park KC, Shepherd JE et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J. Nucl. Med. 2000; 41: 1177-89.
20. Valk PE, Abella-Columna E, Haseman MK et al. Whole-body PET imaging with [(18) F]Fluorodeoxyglucose in management of recurrent colorectal cancer. Arch. Surg. 1999; 134: 503-11.
21. Vitola JV, Delbeke D, Sandler MP et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am. J. Surg. 1996; 171: 21-6.
22. Kalff V, Hicks RJ, Ware RE, Hogg A, Binns D, McKenzie AF. The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J. Nucl. Med. 2002; 43: 492-9.
23. Whiteford MH, Whiteford HM, Yee LF et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis. Colon Rectum 2000; 43: 759-70.
24. Flamen P, Stroobants S, Van Cutsem E et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D- glucose in recurrent colorectal cancer. J. Clin. Oncol. 1999; 17: 894-901.